Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549959 | 0.84 | AKT1 (0.41) | AKT1AKT2DRD2MAPT | |
| SCHEMBL2191957 | 0.84 | MAPT (0.46) | AKT1AKT2DRD2MAPT | |
| SCHEMBL12196104 | 0.84 | MAPT (0.41) | AKT1AKT2DRD2ALDH1A1MAPT | |
| SCHEMBL361871 | 0.83 | AKT1 (0.42) | AKT1AKT2ALDH1A1MAPT | |
| SCHEMBL2505401 | 0.83 | AKT1 (0.42) | AKT1AKT2DRD2ALDH1A1MAPT | |
| SCHEMBL360875 | 0.83 | AKT1 (0.45) | AKT1AKT2DRD2 | |
| SCHEMBL6211955 | 0.82 | MAPT (0.46) | AKT1AKT2DRD2MAPT | |
| SCHEMBL12133148 | 0.82 | RORC (0.39) | AKT1AKT2DRD2 | |
| SCHEMBL14161397 | 0.81 | AKT1 (0.42) | AKT1AKT2DRD2 | |
| SCHEMBL12583792 | 0.81 | L3MBTL1 (0.41) | AKT1AKT2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569331-B2 | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds | ARQULE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569331-B2 | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds | ARQULE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2012061342-A2 | SUBSTITUTED BENZO-IMIDAZO-PYRIDO-DIAZEPINE COMPOUNDS | ARQULE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | ARQULE, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | ARQULE, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | BRD4, BRPF3, BRD3 | AKT1 3524/4885AKT2 2973/4885GSK3B 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.